See more : Shandong Sito Bio-technology Co., Ltd. (300583.SZ) Income Statement Analysis – Financial Results
Complete financial analysis of SpringWorks Therapeutics, Inc. (SWTX) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of SpringWorks Therapeutics, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- Asberry 22 Holdings Inc (ASHI) Income Statement Analysis – Financial Results
- Franklin Leasing and Finance Limited (FRANKLIN.BO) Income Statement Analysis – Financial Results
- bowmo, Inc. (BOMOD) Income Statement Analysis – Financial Results
- La Française des Jeux Société anonyme (LFDJF) Income Statement Analysis – Financial Results
- RRIL LIMITED (RRIL.BO) Income Statement Analysis – Financial Results
SpringWorks Therapeutics, Inc. (SWTX)
About SpringWorks Therapeutics, Inc.
SpringWorks Therapeutics, Inc. acquires, develops, and commercializes medicines for underserved patient populations suffering from rare diseases and cancer. Its lead product candidate is nirogacestat, an oral small molecule gamma secretase inhibitor that is in Phase III clinical trial for the treatment of desmoid tumors. The company is also developing mirdametinib, an oral small molecule MEK inhibitor that is in Phase 2b clinical trials for the treatment of neurofibromatosis type 1-associated plexiform neurofibromas, as well as Phase 1/2a clinical trial for the treatment of NF1-PN; mirdametinib + lifirafenib, a combination therapy that is in Phase 1b/2 clinical trial in patients with advanced or refractory solid tumors; and mirdametinib in monotherapy and combination approaches to treat solid tumors. In addition, it develops BGB-3245, an oral selective small molecule inhibitor of monomeric and dimeric forms of activating BRAF mutations, which is in Phase I clinical trial. The company has collaborations with BeiGene, Ltd., GlaxoSmithKline LLC, and Allogene to develop combination approaches with nirogacestat and mirdametinib; and license agreements with Pfizer Inc. for nirogacestat and mirdametinib. It also has a license agreement with Katholieke Universiteit Leuven and the Flanders Institute for Biotechnology for a portfolio of novel small molecule inhibitors of the TEA Domain; and Dana-Farber Cancer Institute for a portfolio of novel small molecule inhibitors of Epidermal Growth Factor Receptor. In addition, the company has clinical collaboration agreement with Janssen Biotech, Inc., Precision BioSciences, Inc., Seagen Inc., and AbbVie, Inc. SpringWorks Therapeutics, Inc. was founded in 2017 and is headquartered in Stamford, Connecticut.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|
| Revenue | 5.45M | 6.15M | 0.00 | 35.00M | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 422.00K | 1.90M | 490.00K | 349.00K | 192.00K | 17.33K | 3.18K |
| Gross Profit | 5.03M | 4.25M | -490.00K | 34.65M | -192.00K | -17.33K | -3.18K |
| Gross Profit Ratio | 92.25% | 69.16% | 0.00% | 99.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 150.49M | 146.12M | 101.68M | 51.86M | 42.55M | 9.90M | 2.80M |
| General & Administrative | 197.55M | 134.55M | 71.79M | 29.47M | 16.69M | 8.59M | 5.58M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -3.73M |
| SG&A | 197.55M | 134.55M | 71.79M | 29.47M | 16.69M | 8.59M | 1.86M |
| Other Expenses | 0.00 | -138.00K | -152.00K | 25.00K | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 348.04M | 280.67M | 173.47M | 81.32M | 59.24M | 18.49M | 4.66M |
| Cost & Expenses | 348.46M | 280.67M | 173.47M | 81.32M | 59.24M | 18.49M | 4.66M |
| Interest Income | 22.95M | 6.15M | 698.00K | 1.33M | 3.55M | 678.00K | 63.00K |
| Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 1.67M | 1.90M | 490.00K | 349.00K | 192.00K | 17.33K | 3.18K |
| EBITDA | -341.35M | -280.67M | -172.98M | -45.98M | -59.05M | -18.47M | -4.64M |
| EBITDA Ratio | -6,266.68% | -4,566.03% | 0.00% | -131.36% | 0.00% | 0.00% | 0.00% |
| Operating Income | -343.01M | -280.67M | -173.47M | -46.32M | -59.24M | -18.49M | -4.66M |
| Operating Income Ratio | -6,297.28% | -4,566.03% | 0.00% | -132.35% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 17.91M | 3.26M | -442.00K | 750.00K | 933.00K | 678.00K | 21.00K |
| Income Before Tax | -325.10M | -277.42M | -173.91M | -45.57M | -58.31M | -17.81M | -4.64M |
| Income Before Tax Ratio | -5,968.50% | -4,513.05% | 0.00% | -130.21% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | -3.26M | -698.00K | -1.33M | -3.55M | 678.00K | -2.00 |
| Net Income | -325.10M | -274.16M | -173.21M | -44.24M | -54.76M | -17.81M | -4.64M |
| Net Income Ratio | -5,968.50% | -4,460.06% | 0.00% | -126.41% | 0.00% | 0.00% | 0.00% |
| EPS | -5.15 | -5.14 | -3.57 | -1.02 | -1.27 | -0.80 | -0.11 |
| EPS Diluted | -5.15 | -5.14 | -3.57 | -1.02 | -1.27 | -0.80 | -0.11 |
| Weighted Avg Shares Out | 63.12M | 53.29M | 48.50M | 43.30M | 43.01M | 22.20M | 43.23M |
| Weighted Avg Shares Out (Dil) | 63.12M | 53.29M | 48.50M | 43.30M | 43.01M | 22.20M | 43.23M |
SpringWorks Therapeutics Announces Presentation of Additional Data from Phase 3 DeFi Trial of Nirogacestat in Adults with Desmoid Tumors at the 2023 ASCO Annual Meeting
SpringWorks Therapeutics to Participate in the TD Cowen 4th Annual Oncology Innovation Summit
SpringWorks Therapeutics Announces Clinical Data Presentations of Nirogacestat in Combination with BCMA-Directed Therapies at the European Hematology Association 2023 Congress
SpringWorks Therapeutics Reports First Quarter 2023 Financial Results and Recent Business Highlights
SpringWorks Therapeutics to Participate in the Bank of America Securities 2023 Health Care Conference
MapKure, BeiGene and SpringWorks Present Clinical Data on BGB-3245, a Selective Next-Generation B-RAF Inhibitor, in Adult Patients with Advanced or Refractory Solid Tumors at the American Association for Cancer Research Annual Meeting 2023
BeiGene and SpringWorks Present Clinical Data on Lifirafenib, in Combination with Mirdametinib, in Patients with Advanced or Refractory Solid Tumors with MAPK Pathway Aberrations at the American Association for Cancer Research Annual Meeting 2023
SpringWorks and BeiGene Present Clinical Data on Lifirafenib, in combination with Mirdametinib, in Patients with Advanced or Refractory Solid Tumors with MAPK Pathway Aberrations at the American Association for Cancer Research Annual Meeting 2023
BeiGene and SpringWorks Present Clinical Data on Lifirafenib, in Combination with Mirdametinib, in Patients with Advanced or Refractory Solid Tumors with MAPK Pathway Aberrations at the American Association for Cancer Research Annual Meeting 2023
MapKure, BeiGene and SpringWorks Present Clinical Data on BGB-3245, a Selective Next-Generation B-RAF Inhibitor, in Adult Patients with Advanced or Refractory Solid Tumors at the American Association for Cancer Research Annual Meeting 2023
Source: https://incomestatements.info
Category: Stock Reports